Roche is to relaunch its implantable drug-device Susvimo for the treatment of neovascular, age-related macular degeneration (AMD) after nearly two years away from the market.
Roche’s Susvimo Returns, But Destined To Be Vabysmo’s Support Act
The implantable eye treatment will be back on the market soon, but risk of eye infections and complications remain higher than with injectable treatments, meaning it will play second fiddle to Vabysmo.
